Gilead increases activities in NASH sector: deal with Korea-based Yuhan reached

Gilead Sciences has announced it has entered into a cooperation agreement with Korea-based Yuhan Corporation, aimed finding new therapies to treat Non-Alcoholic Steatohepatitis (NASH). The agreement grants Gilead access to two molecules developed by Yuhan, in exchange for a $15m payment, plus an additional maximum of $770m subject to fulfillment of precise milestones.

NASH is a widespread condition in the US, where it affects over 15 million people.